TET2 and leukemia: In the non-malignant samples, TET2, ASXL1, PDS5B, NUP214, and SMC1A were recurrently mutated underlining that some variants may occur as early events (e.g., TET2) providing growth advantage possibly leading to overt leukemia [15].